Pipeline growth and diversification into neurology, rheumatology, ophthalmology, cardiology, and rare disease necessitate ...
CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina ...
CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina Varshavsky-Yanovsky, MD, PhD. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...
Metabolic disease is reshaping care delivery and costs, with experts at the Academy of Managed Care Pharmacy (AMCP) 2026 ...
Despite high rates of grade 3/4 infection, teclistamab was granted full approval by the FDA. Ajay K. Nooka, MD, speaks on how ...
World Hemophilia Day spotlights the rare blood disorder that prevents the blood from clotting and can be dangerous when left ...
The new report explained that the link between psoriasis and sleep disorders “is likely multifactorial, driven by ...
This analysis uses claims and electronic health records from 2021 to examine racial and ethnic variations in immune-mediated inflammatory diseases in the United States. Objectives: Few studies have ...
Ultimate disposition showed 54% approval (7% same-day; 47% after multiple days) and 46% denial, with 27% rejected within 1 ...
Patty Taddei-Allen, PharmD, MBA, examines how co-pay accumulators, maximizers, and AFPs shift costs, impact rebates, and ...
Time-limited acalabrutinib plus venetoclax improves outcomes vs chemoimmunotherapy, offering the first FDA-approved all-oral fixed-duration CLL option, explains Adam Kittai, MD.
Ben Urick, PharmD, PhD, examines GLP-1 coverage gaps and real-world evidence challenges shaping payer decisions and obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results